TY - JOUR ID - 65599 TI - Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: a Systematic Review and GRADE Approach JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 AU - Yang, Wenjie AU - Wang, Dandan AU - Huang, Litao AU - Chen, Yue AU - Wen, Shu AU - Hong, Qi AU - Kang, Deying AD - Department of Evidence-Based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, China. AD - Department of Thoracic Oncology, Cancer Center, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, Medical School, Sichuan University, Chengdu, China. AD - West China School of Medicine and West China Hospital, Sichuan University, Chengdu, China. Y1 - 2018 PY - 2018 VL - 19 IS - 8 SP - 2043 EP - 2055 KW - Carcinoma, Hepatocellular KW - Chemoembolization KW - Thalidomide KW - Systematic review DO - 10.22034/APJCP.2018.19.8.2043 N2 - Objective:According to current guidelines, there is no clear second-line treatment for advanced liver cancer.In practice, clinicians have attempted to use thalidomide(TLD) combined with transcatheter arterial chemoembolization(TACE) for treating liver cancer. This study aims to assess the clinical efficacy and safety of TLD combined with TACEin patients with intermediate or advanced hepatocellular carcinoma. Methods: Medline, Embase, the Cochrane CentralRegister of Controlled Trials (CENTRAL), database of ClinicalTrials.gov, CBM, CNKI, VIP and Wanfang databasewere searched for eligible studies. Criteria for inclusion in our meta-analysis included a study that patients diagnosedwith intermediate or advanced HCC, the use of TACE plus TLD or its derivatives, and the availability of outcomedata for survival. A meta-analysis was conducted to summarize the evidences of randomized controlled trials (RCTs).And finally, the GRADE approach was used to assess the quality of these evidences. Results: Twelve RCTs involving894 Hepatocellular Carcinoma (HCC) patients were included. The meta-analysis results showed that TACE plus TLD wassignificantly superior than TACE alone in terms of 12-month survival rate (OR=2.55, 95% CI:1.78-3.64, P<0.01), 24-monthsurvival rate (OR=2.95, 95% CI:1.96-4.44, P<0.01), 36-month survival rate (OR=2.95, 95% CI:1.41-6.19, P<0.004),progression-free survival (PFS) (MD=2.23, 95% CI:1.19-3.28 , P<0.001), objective response rate (OR=1.84, 95%CI:1.34-2.52, P<0.0001), and disease control rate (OR=2.68, 95% CI:1.80-3.99). Subgroup analysis demonstratedno differences across related outcomes. Sensitivity analyses showed no important differences in the estimates ofeffects. Quality of evidence for all outcomes was rated moderate to very low after applying GRADE approach.Conclusions: Current evidence seemed to support the suggestion that TACE plus TLD as the second line treatment forpatients with intermediate or advanced HCC. However, this finding is not definitive due to the poor quality of includedstudies, more carefully designed and conducted RCTs are warranted to confirm above conclusions. UR - https://journal.waocp.org/article_65599.html L1 - https://journal.waocp.org/article_65599_4c4bb39346379892fa02e3f30247bd8c.pdf ER -